CD20 ANTIBODIES AND USES THEREOF
First Claim
1. An antibody or fragment thereof that specifically bind to a CD20, wherein said antibody or fragment is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
1 Assignment
0 Petitions
Accused Products
Abstract
CD20 is a transmembrane protein of the tetra-spanin family expressed on the surface of B-cells and has been found on B-cells from peripheral blood as well as lymphoid tissues. CD20 expression persists from the early pre-B cell stage until the plasma cell differentiation stage. Conversely, it is not found on hematopoietic stem cells, pro-B cells, differentiated plasma cells or non-lymphoid tissues. In addition to expression in normal B-cells, CD20 is expressed in B-cell derived malignancies such as non-Hodgkin'"'"'s lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). CD20 expressing cells are known to play a role in other diseases and disorders, including inflammation. The present invention includes anti-CD20 antibodies, forms and fragments, having superior physical and functional properties; immunoconjugates, compositions, diagnostic reagents, methods for inhibiting growth, therapeutic methods, improved antibodies and cell lines; and polynucleotides, vectors and genetic constructs encoding same.
-
Citations
92 Claims
- 1. An antibody or fragment thereof that specifically bind to a CD20, wherein said antibody or fragment is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
-
4. An antibody or fragment thereof produced by the hybridoma (ATCC Accession No. PTA-10485) or hybridoma (ATCC Accession No. PTA-10561).
-
45. An antibody or fragment thereof comprising at least one complementarity-determining region having an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 23-28 and 31-37.
- View Dependent Claims (46)
-
47. An antibody or fragment thereof comprising at least one heavy chain and at least one light chain, wherein said heavy chain comprises three sequential complementarity-determining regions having the amino acid sequences of SEQ ID NOS:
- 26-28 or 34, 35 and 37 and wherein said light chain comprises three sequential complementarity-determining regions having the amino acid sequences of SEQ ID NOS;
23-25 or 31-33. - View Dependent Claims (48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)
- 26-28 or 34, 35 and 37 and wherein said light chain comprises three sequential complementarity-determining regions having the amino acid sequences of SEQ ID NOS;
-
64. An improved antibody or fragment that specifically bind to a CD20, prepared by:
-
(a) providing a DNA encoding an antibody or fragment thereof comprising at least one sequence selected from the group consisting of SEQ ID NOS;
1-8, 13-16, and 23-37;(b) introducing at least one nucleotide mutation, deletion or insertion into said DNA such that the amino acid sequence of said antibody or antibody fragment encoded by said DNA is changed; (c) expressing said antibody or antibody fragment; (d) screening said expressed antibody or antibody fragment for said improvement, whereby said improved antibody or antibody fragment is prepared. - View Dependent Claims (65, 66, 68, 69, 70, 71)
-
-
67. An antibody or fragment thereof comprising a polypeptide comprising at least one member selected from the group consisting of SEQ ID NOs:
- 1-8, 13-16, and 23-37.
- 74. A method for treating a patient having a cancer comprising administering to said patient an effective amount of the antibody or fragment or conjugate thereof that specifically bind to a CD20, wherein said antibody or fragment is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
- 81. A method for treating a patient having an autoimmune or inflammatory disease comprising administering to said patient an effective amount of the antibody or fragment or conjugate thereof that specifically bind to a CD20, wherein said antibody or fragment is capable of inducing antibody dependent cell mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).
-
88. A means for specifically binding to a CD20, wherein said means is capable of inducing ADCC and CDC.
Specification